Thyrocare Technologies Limited — Updates, 23-01-2025: Press Release

Thyrocare Technologies Limited reported strong financial performance for the quarter ending December 31, 2024, with consolidated revenue reaching INR 165.9 Cr, marking a 23% increase year-over-year (YoY). The growth was driven by both Pathology and Radiology segments, which saw revenue increases of 24% and 13% YoY, respectively. Franchise revenue surged by 24% YoY, while partnership revenue grew by 23% YoY. The company maintained a robust consolidated gross margin of 73%, with a normalized EBITDA margin of 30%. Standalone EBITDA rose by 32% YoY, and profit after tax (PAT) increased by 30% YoY. The outlook remains positive as Thyrocare continues to expand its footprint as India's only 100% NABL accredited national diagnostic laboratory chain, emphasizing quality and affordability in diagnostic services. Investors should watch closely for sustained growth in both revenue and profitability metrics in the upcoming quarters.